Steve Carr's group has used quantitative proteomics (SILAC) and affinity enrichment to provide "unbiased, robust and comprehensive identification" of the proteins that bind to small-molecule probes and drugs. They say the method is scalable and general and, in this paper, apply it to identify targets of kinase inhibitors and immunophilin binders.